GSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus ...

The European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin ...

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third ...

GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...

GSK (GSK) announced the European Commission has approved Jemperli, or dostarlimab, in combination with chemotherapy for first-line treatment of ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

European regulators have expanded the usage of GSK's Jemperli drug for endometrial cancer, the pharmaceutical firm announced ...

GSK plc (GSK, GSK.L) announced the European Commission has approved Jemperli in combination with chemotherapy for first-line ...

Scientists at a university in the UK are in the midst of creating a breakthrough vaccine that could stop cancer in its tracks ...

advanced or recurrent endometrial cancer in adult patients who are candidates for systemic therapy. In the past year, shares of GSK have lost 15.4% compared with the industry’s decline of 14.2%.

London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...